Introduction
The use of proteins in industrial and pharmaceutical applications has become increasingly common. For example, many monoclonal antibodies (mAbs) are currently in the pipeline of biopharmaceutical drug development due to their high binding strengths and specificities. However, antibodies are susceptible to aggregation and degradation at elevated concentration. At the higher concentrations currently reached in industrial production titers, proteins tend to aggregate and usually lose their potency. Protein drug formulations containing aggregates are known to cause an immunogenetic response and cannot be used. Preparation of very high concentration of these antibodies at a very low volume per dose is critical.
Therefore, predicting or quickly measuring aggregation behavior is paramount for
proper formulation development of protein-based biopharmaceuticals.
Modern biochemistry relies on the structural information provided by protein crystallization to understand fundamental mechanisms of action. Knowledge of protein solubility is crucial for understanding the crystal growth and crystallization process of proteins. In the native state, proteins can be crystallized by the addition of a precipitating agent, which may for example be a neutral salt, a high molecular weight polymer such as PEG, or a small organic compound such as methylpentanediol [1, 2] . The addition of salts, like NaCl, screens the protein charges, progressively leading to protein-protein interactions and eventually to F o r P e e r R e v i e w 3 protein crystallization [3] . Growing evidence suggests that protein crystallization can be understood in terms of phase transition in a system of weakly attractive particles [4] . Controlling these attractions is essential for growing the crystals. However, a priori prediction of protein pair potentials governing these attractions is a difficult task and remains a significant challenge in determining crystallization conditions.
Experimental methods for characterizing the influence of solution conditions (pH, ionic strength, temperature, etc.) on the pair potential would provide the experimentalist with the opportunity to make predictions about how these variables will influence solubility, phase behavior and eventual crystallization.
Protein-protein interaction phenomena occur throughout the range of pharmaceutical protein-processing environments: inclusion body formation in fermentation operations; aggregation as a competitive reaction to refolding; precipitation steps;
and inadvertent crossings of solubility thresholds in purification and finishing processes [5] . Underlying all of these areas is physical protein stability. Physical protein stability can roughly be defined as the inability for a protein to form protein aggregates, protein crystals or an amorphous protein in a stored solution. Physical stability differs from chemical stability in that no chemical modifications of the protein or peptide occur. Measuring realistic protein solubility is hampered by the ability of proteins to supersaturate. Supersaturated solutions generally are not physically stable over storage periods of months or years. Physical protein stability is a particularly relevant issue today in the pharmaceutical field, as indicated above, and will continue to gain more importance as the number of therapeutic protein products in development increases.
Protein-protein self-interactions under varying conditions are important, and screening tools are being developed. One of the parameters capturing protein-protein self-interactions is the osmotic second virial coefficient (B 22 screened using self-interaction chromatography (SIC). The aim of this paper is to review the important factors governing protein solution stability and protein crystallization propensity, and to describe the novel SIC methodology and its application in protein stability and crystallization studies. This is exemplified by a detailed description of the methodology and some recent developments in miniaturizing the method. Finally, some examples from industry are given utilizing this approach.
Osmotic second virial coefficient (B 2)

History of B 22 as a predictor of crystallization conditions
Dynamic laser scattering has been used to study the change in the state of aggregation of protein solutions during nucleation and post-nucleation growth [6] and also to estimate the particle-size distribution in the protein aggregate mixture [7] . Results from these types of experiments have been used to postulate the existence of a critical nucleus to sustain growth [8, 9] and to differentiate between the formation of craggs (aggregates which eventually result in protein crystals) and praggs (aggregates which eventually result in amorphous protein precipitates) [10] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
where N is the total amount of immobilized protein molecules (g) accessible for mobile protein molecules and M w is the molecular weight of the protein (g/mol). V 0 (mL) and V r (mL) are the retention volumes in protein-free column and proteinimmobilized column, respectively.
Retention time of the mobile phase protein is higher when attracting interaction takes place between the mobile-phase protein and immobilized protein on the SIC column.
On the other hand, the retention time is shorter when the interaction is repulsive. In 
Micro-SIC technology
Rapid This successful miniaturization to a microchip level of measurement device for protein self-interaction data is a first key step to a complete microfluidic screening platform for the rational design of protein crystallizations, using substantially less expensive protein and experimentation time. 
Micro-SIC
Microfluidic (or lab-on-a-chip) technologies are gaining ground in the biological and medical sciences and offer a suitable platform for high-throughput screening technologies [60] [61] [62] [63] . Proteins present a particular challenge in microfluidic devices because of the need to maintain structural integrity when attached to a number of different surface geometries and chemistries [50] . Several strategies have been used to address the issue of protein-wall interactions [64, 65] . One of the approaches is to chemically alter the silica surface by coating with linear polyacrylamide or other hydrophilic functional polymers. The interaction of proteins with the silica surface through an ion-exchange mechanism is believed to be responsible for degrading the efficiency and reproducibility of the immobilization process [64] . Nevertheless, there
have been a number of recent reports where proteins, including enzymes, have been incorporated into micro-channels while maintaining biological activity [66] . Highthroughput analysis of protein-protein interactions in a microfluidic platform can be achieved by carefully selecting the protein immobilization strategy that allows the protein to retain its biological activity. 
How to use SIC for stable protein formulation?
The number of protein-based therapeutic products is growing. The main issues in developing these products are in-process stability and solubility. In addition to the stability during the manufacturing process, the protein formulation products should (Fig. 6a) . This positive shift in the trend of B 22 was in strong qualitative agreement with the marked increase in the enzymatic activity (Fig. 6b) . This was not only an indicator of co-solvent-induced physical stability of the amylase, but also indicated an important role of SIC, via a B 22 screen, for rational formulation screening of more industrially relevant enzymes.
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